AngioSoma to Upgrade Its OmniCath Patents into OmniCath 2 Atherectomy Catheter

AngioSoma, Inc. (OTCQB: SOAN) announces today that it is filing new improvements to its US Patent No. 5,728,129 and five predecessor patents 4,850,957; 4,994,067; 5,087,265; and 5,695,519; all of which will be used as “prior art” to its newest catheter, the OmniCath 2. With the new improvements being added, the OmniCath 2 may be the most versatile debulking and vessel remodeling atherectomy catheter available for endovascular interventional procedures in treating coronary and peripheral artery diseases resulting in plaque-atherosclerosis. The new improvements include:

• a plaque cutting mechanism that allows cutting from either (a) the
  end-tip to first recanalize the blocked lumen, then (b) a further step
  of completely debulking the lesion using the directional side-window;
• discrete angioplasty balloon proximal (upstream) to blood flow
  allowing for second step angioplasty and vessel wall remolding;
• using the same balloon for optional upstream blocking of blood flow
  allowing simultaneous saline irrigation and clear endoscopic view from
  the side-cutting window or most distal tip, or for video feed giving
  the operator/physician precise visual control; and
• completely detachable and disposable catheter shaft, driveline,
  cutter, and angioplasty balloon from motor assembly
  preventing cross contamination of infections such as MRSA while
  allowing reuse of its lithium battery powered motor.

Per CEO Alexanderia K. Blankenship, “The OmniCath 2 will be priced
competitively with both balloon catheters and atherectomy devices
providing physicians with a multiplicity of easy options.” The
company estimates that it may be able to achieve sales of over $1
billion annually when fully integrated into the market.
ABOUT ANGIOSOMA, INC.
AngioSoma, Inc. (https://www.angiosoma.com)
is a clinical stage biopharmaceutical company focused on improving the
effectiveness of current standard-of-care treatments, especially related
to endovascular interventions in the treatment of peripheral artery
disease (‘PAD‘). Our lead pharmaceutical product Liprostin™, a
treatment for PAD, has successfully completed FDA Phase I and three
Phase II clinical trials, and we are in discussions with several
contract research organizations for rapid completion of our U.S. Food
and Drug Administration (‘FDA‘) approved protocol for Phase III
with submission of our new drug application for marketing in the U.S.
and its territories.
NOTICE REGARDING FORWARD LOOKING STATEMENTS
This news release contains forward-looking information within the
meaning of Section 27A of the Securities Act of 1933 and Section 21E of
the Securities Exchange Act of 1934, including statements that include
the words “believes,” “expects,” “anticipate” or
similar expressions. Such forward-looking statements involve known and
unknown risks, and other factors that may cause the actual results,
performance or achievements of the company to differ materially from
those expressed or implied by such forward-looking statements. In
addition, description of anyone’s past success is no guarantee of future
success. This news release speaks as of the date first set forth above
and the company assumes no responsibility to update the information
included herein for events occurring after the date hereof.